Veeva Systems (VEEV) Q4 2026 earnings review
A Flawless Finish to FY26, But Growth is Decelerating Into FY27
Veeva crushed its Q4 expectations, delivering $836.0M in revenue (+16% YoY) against a $807-$810M guidance. The non-GAAP EPS of $2.06 significantly outpaced the $1.92 target. The 'agentic transformation' (AI integration) and the continued shift to Vault CRM drove a breakout year. Operating leverage is stable and impressive, with Non-GAAP operating margins near 44%. However, the market will need to digest the FY27 guidance: management is projecting total revenue of $3.585-$3.6B, which implies a decelerating ~12.4% YoY growth rate compared to the 16% achieved in FY26. The shift from a hyper-growth SaaS to a mature, compounding cash-flow machine is fully underway.
🐂 Bull Case
Veeva is no longer just a CRM company. R&D and Quality Solutions revenue surpassed Commercial Solutions by a wide margin ($1.42B vs $1.25B in FY26), proving the 'Industry Cloud' model is robust and resilient.
A 44.9% FY26 Non-GAAP operating margin on 16% top-line growth places Veeva in the elite tier of enterprise software. The company generated over $1.4B in operating cash flow.
🐻 Bear Case
The FY27 guidance implies roughly 12.4% YoY top-line growth. While highly profitable, this marks a steady deceleration from historical 16-20% rates, which may compress valuation multiples.
While 10 of the top 20 biopharmas have committed to Vault CRM, prior management commentary indicated that 6 definitively opted for competitors. Veeva is bleeding some market share at the absolute top end of the market.
⚖️ Verdict: 🟢
Bullish, but price-sensitive. Execution is spectacular and the moat in life sciences remains incredibly deep. However, the guided deceleration to ~12% growth requires investors to buy into the cash-flow compounding story rather than pure hyper-growth.
Key Themes
R&D and Quality Cloud Overtakes Commercial
Stable and accelerating. Veeva R&D and Quality Solutions subscription revenues hit $380.8M in Q4 (+20.8% YoY), significantly outpacing Commercial Solutions subscriptions ($327.0M, +11.4% YoY). Major wins included a top 20 biopharma selecting Veeva RTSM as their enterprise standard, and the first top 20 biopharma going live on Workbench and Signal. This segment is the undisputed growth engine.
Vault CRM Migrations Gaining Scale
Accelerating. Veeva now has over 125 customers live on Vault CRM (up from 115 in Q3 and 80 in Q1). Two top 20 biopharmas are already live in major markets. Getting the installed base off the legacy Salesforce-based CRM and onto the proprietary Vault platform secures long-term margins and cross-sell opportunities (Service Center, Patient CRM).
Crossix and Data Products Firing on All Cylinders
Stable. The Commercial Cloud's growth is heavily subsidized by Crossix, which management noted had a 'breakout year' with strong growth in Measurement and Audiences. Digital marketing optimization for pharma remains a high-ROI, resilient spend category.
Top-Line Growth Guidance Decelerating
Decelerating. FY26 delivered 16% YoY total revenue growth. The updated FY27 guidance of $3.585B to $3.600B represents a notable slowdown to ~12.4% YoY growth at the midpoint. This shift indicates the law of large numbers is catching up, and future returns will lean more heavily on operating leverage than pure sales expansion.
The 'Missing 10' in Vault CRM
Stable risk. The PR touts that '10 top 20 biopharmas committed to Vault CRM globally.' While framed positively, this specifically contradicts the narrative of complete market dominance, as it means the other 10 have not committed. We know from Q3 transcripts that 6 of these definitively chose not to migrate, opting for competitors (likely Salesforce). This represents a permanent structural loss of some high-end market share.
Macroeconomic Uncertainty and Long Sales Cycles
Stable. As noted in prior quarters, the macro environment remains uncertain due to potential changes in US drug pricing, FDA dynamics, and biotech funding constraints. For core enterprise R&D systems (like Safety or LIMS), customers make 10-year decisions, resulting in inherently long and slow sales cycles that can delay revenue realization in uncertain times.
Veeva AI: Deep, Agentic Transformation
Accelerating. Veeva released its first AI Agents for CRM and commercial content in December. The approach is highly pragmatic: rather than building foundational LLMs, Veeva is deeply integrating 'agents' into core systems of record (e.g., TMF document filing, Safety case processing). Management expects this to create immense structural value by replacing outsourced human labor in life sciences.
Other KPIs
Accelerating. Up nearly 30% from $1.09B in FY25. The cash generation is staggering, converting over 44% of total revenue into operating cash flow. This fortress balance sheet (ending the year with $6.56B in cash and short-term investments) provides massive optionality for strategic M&A or capital returns.
Stable. Stock-based compensation grew 8% YoY from $437.3M in FY25. Crucially, SBC as a percentage of total revenue actually decreased from 15.9% in FY25 to 14.8% in FY26. Management is demonstrating excellent discipline in managing equity dilution compared to many enterprise SaaS peers.
Guidance
Decelerating. The midpoint ($856.5M) implies a 12.8% YoY growth rate compared to 26Q1's $759.0M. This is a step down from the 16% YoY growth just achieved in 26Q4.
Stable. The midpoint of $379.5M implies an operating margin of 44.3%. While incredibly healthy, it represents a slight quarter-over-quarter compression from 26Q3's 45.0%, suggesting investments in AI and Vault CRM migrations are requiring continued spend.
Decelerating. The midpoint of $3.592B implies roughly 12.4% YoY growth against FY26's $3.195B. Veeva remains highly confident in its long-term $6B target for 2030, but the trajectory to get there is flattening slightly.
Decelerating. Implies a 9.2% YoY growth rate compared to the $8.10 achieved in FY26. Earnings growth lagging top-line growth (12.4%) indicates that peak margin expansion may be behind the company, with higher normalized tax rates or heavier R&D/Services headcount investment in the mix.
Key Questions
Margin Ceilings and Earnings Leverage
FY27 EPS guidance implies 9% YoY growth, trailing the 12% revenue growth guidance. After years of margins expanding faster than revenues, have we hit the ceiling on operating leverage? What are the primary margin headwinds in FY27?
Vault CRM 'Win-Backs'
You noted 10 of the top 20 biopharmas are committed to Vault CRM. For the subset of the top 20 that explicitly chose not to migrate, what is the strategy and realistic timeline for attempting a 'win-back'?
Horizontal CRM Timeline
In earlier quarters, you mentioned an ambitious entry into Horizontal CRM outside of life sciences. Has the timeline or investment priority for this changed given the focus on AI Agents and Vault CRM migrations?
AI Monetization Mechanics
With the release of the first AI Agents in December, how will these be monetized in FY27? Are they included to drive overall platform stickiness, or will they be licensed as separate add-on SKUs that drive immediate ACV uplift?